Trial intelligence / Profile preview

Cyclosporine versus methotrexate versus standard of care in children and adolescents with moderate-to-severe atopic dermatitis

2020-004194-51Phase 3Active

Sponsor
Medical University of Lodz
Start
Nov 2020
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 3, randomised, open-label trial in atopic dermatitis (AD) comparing Cyclosporine monotherapy, Methotrexate monotherapy and Standard of care (3 arms). Primary endpoint: EASI75 at week 32. Started Nov 2020; status: active.

02

Drugs

cyclosporinemethotrexate
03

Conditions

atopic dermatitis (AD)

Beyond the preview

Go deeper on 2020-004194-51.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2020-004194-51.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call